Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.

Takashi Ishikawa,Kouhei Akazawa,Yoshie Hasegawa,Hirokazu Tanino,Jun Horiguchi,Daishu Miura,Mitsuhiro Hayashi,Norio Kohno

Journal of Surgical Research（2017）

引用 13|浏览24

暂无评分

摘要

ZOL did not improve DFS when combined with CT. However, the improvement of the pCR rate translated to survival outcomes in TN breast cancer. The short-term application of ZOL may not be sufficient to improve the outcome in postmenopausal patients.

查看译文

关键词

HER2-negative breast cancer,Neoadjuvant chemotherapy,Zoledronic acid,Disease-free survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要